eanpages
  • General interest
    • All Executive Page Paper of the Month EAN News EAN Congress news COVID-19 Interviews
      EAN News

      EAN endorsed meeting in September 2022

      August 12, 2022

      Executive Page

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      Paper of the Month

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      Executive Page

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      Executive Page

      New EAN President, Prof. Paul Boon, identifies brain health, research agenda, and residents as key priorities

      July 8, 2022

      Executive Page

      Executive Page: packed programme for our happy reunion at EAN 2022 in Vienna

      June 3, 2022

      Executive Page Dear EAN members, dear friends, It is my pleasure to give you an update on behalf of the EAN Scientific Committee following a busy year since my appointment as chair. It has been a privilege to be so deeply involved in the scientific activities of the EAN and to work closely with an amazing community of people who are so dedicated to the advancement of neurology. One of the strongest threads within that community is the EAN’s group of Scientific Panels, which are often referred to as the organisation’s ‘scientific backbone’. The panels have a hand in everything the EAN does from a scientific point of view, including coordinating clinical research, disseminating good practice, assisting in planning the EAN annual congress, supporting the EAN’s educational efforts, and producing guidelines that assist neurologists in daily practice. All of this work requires a considerable amount of oversight, and this is why each panel is run by its own Management Group, elected by the panel members. Being a part of one of these Management Groups (PDF) is an opportunity to play a direct part in determining the direction of scientific progress within Europe, and I am excited to say that the call for applications to stand for election will be announced in September. All panel members and EAN individual members are eligible to apply to be candidates, with the vote being held among the existing panel members in autumn. I would like to urge every neurologist with a passion for the scientific future of their special area of interest to consider standing for election to the relevant Management Group and to look out for the call for applications later this month. I can tell you from personal experience that fulfilling a role such as this within the structure of the EAN is a fascinating and extremely rewarding experience. The chance to take on such a unique leadership position should not be missed! The most satisfying aspect of being involved in the EAN’s organisational structure is surely seeing all the hard work and planning come to fruition when a small idea evolves into a newly launched project. One such example is the 1st EAN Science School, taking place in Salzburg next March. The idea of the Science School is to offer early career neurologists with an interest in translational research a new avenue for learning about basic pathomechanisms of neurological disorders. Application for this very first edition, on ‘Pathophysiology of disorders of the nervous system’, closed last week and we have been delighted with the level of interest. It was a pleasure to be part of the task force in charge of planning this new project and I look forward to seeing it officially transferred to the hands of the Scientific Committee after a successful event and evaluation in spring. Of our ongoing activities, one of the most significant is the EAN Neuro-covid Registry, which aims to collate epidemiological data on neurological manifestations in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms, and hospital departments. We currently have 1,542 patients entered in the database, from 35 centres across 23 countries. So far, 29 patients have been followed for 12 months and 387 have completed the 6-months follow up. This is a decent start, but I would like to strongly encourage EAN members and their institutions to get involved and contribute cases to what will become an invaluable resource for neurologists and clinicians to improve care for Covid-19 patients. Finally, I would like share a word on a forthcoming collaboration between EAN and the Human Brain Project in December, that I think will interest a lot of EAN members. The EAN-EBRAINS joint workshop on ‘The future of medical data sharing in clinical neurosciences’ will be a three-day virtual event that aims to discuss issues and challenges associated with data sharing in Europe, from ethics to data safety and privacy, including those specific to data federation, such as the development and validation of federated algorithms. The whole workshop is completely free of charge and registration is open until 25 November, so please check out the details and sign up! I wish you all a healthy and pleasant autumn and I look forward to updating you again. Best wishes Thomas Berger Chair of the EAN Scientific Committee

      Executive Page: Join the EAN Panels and reinforce our scientific backbone! (Plus ENERGY update, and our first Science School)

      May 1, 2022

      Paper of the Month

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      Paper of the Month

      Research Paper of the Month: Association of intraventricular fibrinolysis with clinical outcomes in ICH: an individual participant data meta-analysis

      July 8, 2022

      Paper of the Month

      Covid-19 Paper of the month: Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms

      July 8, 2022

      Paper of the Month

      Research Paper of the Month: Healthy lifestyle and life expectancy with and without Alzheimer’s dementia: population based cohort study

      June 3, 2022

      EAN News

      EAN endorsed meeting in September 2022

      August 12, 2022

      EAN News

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      EAN News

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      EAN Congress news

      Video Interview: Sleep-Wake Panel Co-Chair, Dr. Evelina Pajediene

      July 28, 2022

      EAN Congress news

      Watch the full EAN 2022 Opening Session on our Vimeo channel!

      July 11, 2022

      EAN Congress news

      New EAN President, Prof. Paul Boon, identifies brain health, research agenda, and residents as key priorities

      July 8, 2022

      EAN Congress news

      Video Interview: WFN President, Prof. Wolfgang Grisold

      July 7, 2022

      COVID-19

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      COVID-19

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      COVID-19

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      COVID-19

      COVID-19 Breaking News: Cross-Sectional Case Control Studies – July 2022

      July 18, 2022

      Interviews

      Video Interview: Sleep-Wake Panel Co-Chair, Dr. Evelina Pajediene

      July 28, 2022

      Interviews

      Video: EAN supports World Brain Day

      July 19, 2022

      Interviews

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Interviews

      Video Interview: WFN President, Prof. Wolfgang Grisold

      July 7, 2022

  • Academic/Scientific
    • All Breaking news Neurology updates Scientific committee reports Scientific panels reports Eur J Neurol Top 10 Articles Scientific Corner
      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      Academic/Scientific

      2nd EAN Science School, 18-20 March 2023

      July 20, 2022

      Breaking news

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Cross-Sectional Case Control Studies – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Observational studies – prospective longitudinal cohort – June 2022

      June 8, 2022

      Neurology updates

      Neurology Update: Palliative care

      July 6, 2021

      Neurology updates

      Neurology Update: Clinical Neurophysiology

      June 2, 2021

      Neurology updates Hannover Medical School

      Progressive multifocal leukoencephalopathy – promising therapeutic approach with allogeneic BK virus-specific T cells

      May 17, 2021

      Neurology updates

      Neurology Update: Neuroimmunology

      May 12, 2021

      Scientific committee reports

      Scientific Committee Snapshot: Didier Leys

      April 1, 2020

      Scientific committee reports

      Scientific Committee Snapshot: Rigmor Hojland

      February 26, 2020

      Scientific committee reports

      Scientific Committee Snapshot: Christian Enzinger

      December 1, 2019

      Scientific committee reports

      Scientific Committee Snapshot: Maurizio Leone

      November 1, 2019

      Scientific panels reports

      Coma and DOC Panel Update (May-June): news from the EAN Virtual Congress, personalized pain assessment, NIRS-EEG and machine learning to predict outcomes, prevalence of swallowing disorders and new multimodal predictive algorithms.

      August 11, 2020

      Scientific panels reports

      Statement of the EAN Sleep-Wake-Panel

      June 3, 2020

      Scientific panels reports

      Rare Neurological Diseases in the COVID-19 era: Suggestions for information to patients and caregivers

      May 13, 2020

      Scientific panels reports

      Scentific Panel of the Month: Higher Cortical Functions

      March 2, 2020

      Eur J Neurol

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Eur J Neurol

      EAN NeuroCOVID-19 Task Force position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders

      May 2, 2022

      Eur J Neurol

      European Journal of Neurology welcomes new associate editors

      December 13, 2021

      Eur J Neurol

      New European guideline and expert statements on the management of narcolepsy in adults and children

      June 30, 2021

      Top 10 Articles

      EAN is proud to announce the 2020 Virtual Master Classes Christmas Special

      November 13, 2020

      Top 10 Articles

      EUROPEAN JOURNAL OF NEUROLOGY – TOP 15 ARTICLES 2018

      February 1, 2019

      Top 10 Articles

      Interview with Prof. Patrick Cras – UEMS Section of Neurology (SN)

      February 3, 2018

      Top 10 Articles

      Interview with Mr. Bertrand Daval and Mrs. Nathalie Paulus

      February 3, 2018

      Scientific Corner

      Join the EAN Guideline Workshop on 24 June!

      May 13, 2022

      Scientific Corner

      First EAN Science School proves a hit in Salzburg

      April 1, 2022

      Scientific Corner

      Invitation to the EAN-EBRAINS Joint Workshop on ‘The Future of Medical Data Sharing in Clinical Neurosciences’

      July 2, 2021

      Scientific Corner

      1st EAN Science School, 26-29 March 2022: “Pathophysiology of disorders of the nervous system”

      June 18, 2021

  • Educational
    • All eLearning Student Corner E-Brain Grand Rounds Resident and Research Fellows Fellowship reports Education corner
      Fellowship reports

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Academic/Scientific

      2nd EAN Science School, 18-20 March 2023

      July 20, 2022

      Fellowship reports

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      eLearning

      Listen now to ‘eanCast: Weekly Neurology’ our latest eLearning resource

      July 14, 2022

      eLearning

      EAN Campus: Your source for online neurology education!

      June 24, 2022

      eLearning

      eanCast: Weekly Neurology

      June 24, 2022

      eLearning

      Meet our new eLearning Associate Editors

      August 12, 2021

      Student Corner

      EAN 2022 ‘Why Neurology?’ essay contest winners

      June 2, 2022

      Student Corner

      Students’ Corner: A day in the life of a medical student in your country

      May 20, 2022

      Student Corner

      Student Teaser Fellowship winners 2022

      May 11, 2022

      Student Corner

      ‘Why Neurology?’ student essay competition: win a travel grant for a future EAN Congress!

      March 14, 2022

      E-Brain

      ebrain May update: new website and podcast series

      May 1, 2021

      E-Brain

      EBRA launches 3rd call for clusters

      May 1, 2020

      E-Brain

      News from ebrain

      February 28, 2020

      E-Brain

      ebrain to host the 2019 Neurology Formative Test Questions, from 15 April to 26 May

      April 1, 2019

      Grand Rounds

      eBrain: virtual case report from Belgium

      October 2, 2017

      Grand Rounds

      Free access to Ebrain for EAN members

      July 1, 2016

      Grand Rounds

      Ebrain granted Royal College of Physicians (UK) CPD/CME accreditation

      July 1, 2016

      Grand Rounds

      ebrain session of the month: neuromuscular junction

      February 1, 2016

      Resident and Research Fellows

      Workshop at EAN 2022 raises awareness of mentorship benefits

      July 5, 2022

      Resident and Research Fellows

      First ever UK Regional Teaching Course held in Liverpool, in person

      July 4, 2022

      Resident and Research Fellows

      RRFS Special Session – Unveiling research in Neurology: differences between basic, clinical and translational

      June 25, 2022

      Resident and Research Fellows

      23rd EAN Spring School – Report

      June 24, 2022

      Fellowship reports

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Fellowship reports

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2020 – Institut Necker Enfants Malades, Paris

      July 15, 2022

      Education corner

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Education corner

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Education corner

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      Education corner

      Research Fellowship Report 2020 – Institut Necker Enfants Malades, Paris

      July 15, 2022

  • Other News
    • All EAN Staff Grant opportunities News from EAN member societies EBC EFNA News in general Patients societies reports Surveys Forum
      Other News

      The role of EAN in the European Medicine Agency

      August 2, 2022

      News from EAN member societies

      14 June: Special publication celebrates 10 years of the European Working Group of People with Dementia

      August 2, 2022

      News from EAN member societies

      14 June: Alzheimer Europe hosts European Parliament Lunch Debate examining EU and WHO policies on neurological conditions

      August 2, 2022

      News from EAN member societies

      22 June: Alzheimer Europe invites applications for its new Anti-Stigma Award

      August 2, 2022

      EAN Staff

      EAN Head Office Profiles: Patrycja & Martin

      July 28, 2022

      EAN Staff

      EAN Head Office Profiles: Anja S

      July 12, 2022

      EAN Staff

      EAN Head Office Profiles: Magda & Lindley

      June 7, 2022

      EAN Staff

      EAN Head Office Profiles: Julia & Maria

      April 4, 2022

      Grant opportunities

      1st EAN Science School, 26-29 March 2022: “Pathophysiology of disorders of the nervous system”

      June 18, 2021

      Grant opportunities

      European Commission: Innovation and novelty in medical devices and in vitro diagnostic devices; towards common concepts of innovation-related risk assessments

      November 1, 2019

      Grant opportunities

      GBS|CIDP Foundation International 2020 Research Grant Opportunity

      October 29, 2019

      Grant opportunities

      The Clinical Fellowship application deadline is approaching

      October 1, 2019

      News from EAN member societies

      14 June: Special publication celebrates 10 years of the European Working Group of People with Dementia

      August 2, 2022

      News from EAN member societies

      14 June: Alzheimer Europe hosts European Parliament Lunch Debate examining EU and WHO policies on neurological conditions

      August 2, 2022

      News from EAN member societies

      22 June: Alzheimer Europe invites applications for its new Anti-Stigma Award

      August 2, 2022

      News from EAN member societies

      Alzheimer Europe publishes new reports on ‘sex, gender and sexuality in the context of dementia’, and ‘dementia-inclusive initiatives and communities’

      April 5, 2022

      EBC

      Value of Treatment project releases results and calls to action

      March 29, 2022

      EBC

      Best practices for patient safety: An EU-wide view on the use of medicines off-label

      December 31, 2021

      EBC

      Creating synergies and showcasing innovation: Brain Innovation Days 2021

      November 30, 2021

      EBC

      Best practices for patient safety: Register now!

      October 28, 2021

      EFNA

      OneNeurology European Summit underlines urgent need to prioritise neurology and drive change

      December 31, 2021

      EFNA

      EFNA launch eLearning Platform for neurology advocates

      February 1, 2021

      EFNA

      ‘Me and My Brain’ – Art Competition winners announced!

      February 1, 2021

      EFNA

      Survey on the impact of COVID-19 on neurology service delivery

      November 1, 2020

      News in general

      EAN lecture at the International Neuro-Urology Society annual congress 2022

      May 25, 2022

      News in general

      EPA-EAN Joint Symposium: ‘Etiology and Treatment of the Long Covid-19 Syndrome’ and other highlights at the 30th European Congress of Psychiatry

      May 25, 2022

      News in general

      Organise an EAN-Day or EAN Regional Teaching Course in your Country!

      May 17, 2022

      News in general

      Value of Treatment project releases results and calls to action

      March 29, 2022

      Patients societies reports

      News from Alzheimer Europe

      March 2, 2020

      Patients societies reports

      News from the WHO

      January 9, 2020

      Patients societies reports

      News from EFIC and the European Pain Forum

      January 3, 2020

      Patients societies reports

      News from EFIC and the European Pain Forum

      January 2, 2020

      Surveys

      Survey: management of covert brain infarction

      October 29, 2021

      Surveys

      Driving with an intracranial tumor

      July 13, 2020

      Surveys

      SURVEY: Driving with an intracranial tumor

      June 25, 2020

      Surveys

      EAN SURVEY: Neurological Symptoms in COVID-19 Patients

      April 10, 2020

      Forum

      Call for Applications: e-Learning Platform Editor-in-Chief

      August 4, 2020

      Forum

      Neurological News from Denmark VI – the land of the 2nd EAN congress 2016: Pain Research in Denmark from a neurological perspective

      April 1, 2016

      Forum

      Neurological News from Denmark V – the land of the 2nd EAN congress 2016: Clinical Dementia Research in Denmark

      March 1, 2016

      Forum

      Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri – Comment to EMA recommendation

      March 1, 2016

  • EAN
  • Congress 2022
  • EAN pages
  • Eur J Neurol
  • Virtual Congress

eanpages

  • General interest
    • All Executive Page Paper of the Month EAN News EAN Congress news COVID-19 Interviews
      EAN News

      EAN endorsed meeting in September 2022

      August 12, 2022

      Executive Page

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      Paper of the Month

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      Executive Page

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      Executive Page

      New EAN President, Prof. Paul Boon, identifies brain health, research agenda, and residents as key priorities

      July 8, 2022

      Executive Page

      Executive Page: packed programme for our happy reunion at EAN 2022 in Vienna

      June 3, 2022

      Executive Page Dear EAN members, dear friends, It is my pleasure to give you an update on behalf of the EAN Scientific Committee following a busy year since my appointment as chair. It has been a privilege to be so deeply involved in the scientific activities of the EAN and to work closely with an amazing community of people who are so dedicated to the advancement of neurology. One of the strongest threads within that community is the EAN’s group of Scientific Panels, which are often referred to as the organisation’s ‘scientific backbone’. The panels have a hand in everything the EAN does from a scientific point of view, including coordinating clinical research, disseminating good practice, assisting in planning the EAN annual congress, supporting the EAN’s educational efforts, and producing guidelines that assist neurologists in daily practice. All of this work requires a considerable amount of oversight, and this is why each panel is run by its own Management Group, elected by the panel members. Being a part of one of these Management Groups (PDF) is an opportunity to play a direct part in determining the direction of scientific progress within Europe, and I am excited to say that the call for applications to stand for election will be announced in September. All panel members and EAN individual members are eligible to apply to be candidates, with the vote being held among the existing panel members in autumn. I would like to urge every neurologist with a passion for the scientific future of their special area of interest to consider standing for election to the relevant Management Group and to look out for the call for applications later this month. I can tell you from personal experience that fulfilling a role such as this within the structure of the EAN is a fascinating and extremely rewarding experience. The chance to take on such a unique leadership position should not be missed! The most satisfying aspect of being involved in the EAN’s organisational structure is surely seeing all the hard work and planning come to fruition when a small idea evolves into a newly launched project. One such example is the 1st EAN Science School, taking place in Salzburg next March. The idea of the Science School is to offer early career neurologists with an interest in translational research a new avenue for learning about basic pathomechanisms of neurological disorders. Application for this very first edition, on ‘Pathophysiology of disorders of the nervous system’, closed last week and we have been delighted with the level of interest. It was a pleasure to be part of the task force in charge of planning this new project and I look forward to seeing it officially transferred to the hands of the Scientific Committee after a successful event and evaluation in spring. Of our ongoing activities, one of the most significant is the EAN Neuro-covid Registry, which aims to collate epidemiological data on neurological manifestations in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms, and hospital departments. We currently have 1,542 patients entered in the database, from 35 centres across 23 countries. So far, 29 patients have been followed for 12 months and 387 have completed the 6-months follow up. This is a decent start, but I would like to strongly encourage EAN members and their institutions to get involved and contribute cases to what will become an invaluable resource for neurologists and clinicians to improve care for Covid-19 patients. Finally, I would like share a word on a forthcoming collaboration between EAN and the Human Brain Project in December, that I think will interest a lot of EAN members. The EAN-EBRAINS joint workshop on ‘The future of medical data sharing in clinical neurosciences’ will be a three-day virtual event that aims to discuss issues and challenges associated with data sharing in Europe, from ethics to data safety and privacy, including those specific to data federation, such as the development and validation of federated algorithms. The whole workshop is completely free of charge and registration is open until 25 November, so please check out the details and sign up! I wish you all a healthy and pleasant autumn and I look forward to updating you again. Best wishes Thomas Berger Chair of the EAN Scientific Committee

      Executive Page: Join the EAN Panels and reinforce our scientific backbone! (Plus ENERGY update, and our first Science School)

      May 1, 2022

      Paper of the Month

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      Paper of the Month

      Research Paper of the Month: Association of intraventricular fibrinolysis with clinical outcomes in ICH: an individual participant data meta-analysis

      July 8, 2022

      Paper of the Month

      Covid-19 Paper of the month: Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms

      July 8, 2022

      Paper of the Month

      Research Paper of the Month: Healthy lifestyle and life expectancy with and without Alzheimer’s dementia: population based cohort study

      June 3, 2022

      EAN News

      EAN endorsed meeting in September 2022

      August 12, 2022

      EAN News

      Executive Page: New President-Elect outlines aims for EAN’s future agenda

      August 1, 2022

      EAN News

      Research Paper of the Month: Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke

      August 1, 2022

      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      EAN Congress news

      Video Interview: Sleep-Wake Panel Co-Chair, Dr. Evelina Pajediene

      July 28, 2022

      EAN Congress news

      Watch the full EAN 2022 Opening Session on our Vimeo channel!

      July 11, 2022

      EAN Congress news

      New EAN President, Prof. Paul Boon, identifies brain health, research agenda, and residents as key priorities

      July 8, 2022

      EAN Congress news

      Video Interview: WFN President, Prof. Wolfgang Grisold

      July 7, 2022

      COVID-19

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      COVID-19

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      COVID-19

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      COVID-19

      COVID-19 Breaking News: Cross-Sectional Case Control Studies – July 2022

      July 18, 2022

      Interviews

      Video Interview: Sleep-Wake Panel Co-Chair, Dr. Evelina Pajediene

      July 28, 2022

      Interviews

      Video: EAN supports World Brain Day

      July 19, 2022

      Interviews

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Interviews

      Video Interview: WFN President, Prof. Wolfgang Grisold

      July 7, 2022

  • Academic/Scientific
    • All Breaking news Neurology updates Scientific committee reports Scientific panels reports Eur J Neurol Top 10 Articles Scientific Corner
      EAN News

      Contribute to the EAN Neuro-Covid Registry (ENERGY) and be part of our growing global project

      July 29, 2022

      Academic/Scientific

      2nd EAN Science School, 18-20 March 2023

      July 20, 2022

      Breaking news

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Case Series/Case Reports – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Meta-analyses/systematic reviews – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Cross-Sectional Case Control Studies – July 2022

      July 18, 2022

      Breaking news

      COVID-19 Breaking News: Observational studies – prospective longitudinal cohort – June 2022

      June 8, 2022

      Neurology updates

      Neurology Update: Palliative care

      July 6, 2021

      Neurology updates

      Neurology Update: Clinical Neurophysiology

      June 2, 2021

      Neurology updates Hannover Medical School

      Progressive multifocal leukoencephalopathy – promising therapeutic approach with allogeneic BK virus-specific T cells

      May 17, 2021

      Neurology updates

      Neurology Update: Neuroimmunology

      May 12, 2021

      Scientific committee reports

      Scientific Committee Snapshot: Didier Leys

      April 1, 2020

      Scientific committee reports

      Scientific Committee Snapshot: Rigmor Hojland

      February 26, 2020

      Scientific committee reports

      Scientific Committee Snapshot: Christian Enzinger

      December 1, 2019

      Scientific committee reports

      Scientific Committee Snapshot: Maurizio Leone

      November 1, 2019

      Scientific panels reports

      Coma and DOC Panel Update (May-June): news from the EAN Virtual Congress, personalized pain assessment, NIRS-EEG and machine learning to predict outcomes, prevalence of swallowing disorders and new multimodal predictive algorithms.

      August 11, 2020

      Scientific panels reports

      Statement of the EAN Sleep-Wake-Panel

      June 3, 2020

      Scientific panels reports

      Rare Neurological Diseases in the COVID-19 era: Suggestions for information to patients and caregivers

      May 13, 2020

      Scientific panels reports

      Scentific Panel of the Month: Higher Cortical Functions

      March 2, 2020

      Eur J Neurol

      Video Interview: European Journal of Neurology Award winner, Dr. Jonathan Coutinho

      July 18, 2022

      Eur J Neurol

      EAN NeuroCOVID-19 Task Force position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders

      May 2, 2022

      Eur J Neurol

      European Journal of Neurology welcomes new associate editors

      December 13, 2021

      Eur J Neurol

      New European guideline and expert statements on the management of narcolepsy in adults and children

      June 30, 2021

      Top 10 Articles

      EAN is proud to announce the 2020 Virtual Master Classes Christmas Special

      November 13, 2020

      Top 10 Articles

      EUROPEAN JOURNAL OF NEUROLOGY – TOP 15 ARTICLES 2018

      February 1, 2019

      Top 10 Articles

      Interview with Prof. Patrick Cras – UEMS Section of Neurology (SN)

      February 3, 2018

      Top 10 Articles

      Interview with Mr. Bertrand Daval and Mrs. Nathalie Paulus

      February 3, 2018

      Scientific Corner

      Join the EAN Guideline Workshop on 24 June!

      May 13, 2022

      Scientific Corner

      First EAN Science School proves a hit in Salzburg

      April 1, 2022

      Scientific Corner

      Invitation to the EAN-EBRAINS Joint Workshop on ‘The Future of Medical Data Sharing in Clinical Neurosciences’

      July 2, 2021

      Scientific Corner

      1st EAN Science School, 26-29 March 2022: “Pathophysiology of disorders of the nervous system”

      June 18, 2021

  • Educational
    • All eLearning Student Corner E-Brain Grand Rounds Resident and Research Fellows Fellowship reports Education corner
      Fellowship reports

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Academic/Scientific

      2nd EAN Science School, 18-20 March 2023

      July 20, 2022

      Fellowship reports

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      eLearning

      Listen now to ‘eanCast: Weekly Neurology’ our latest eLearning resource

      July 14, 2022

      eLearning

      EAN Campus: Your source for online neurology education!

      June 24, 2022

      eLearning

      eanCast: Weekly Neurology

      June 24, 2022

      eLearning

      Meet our new eLearning Associate Editors

      August 12, 2021

      Student Corner

      EAN 2022 ‘Why Neurology?’ essay contest winners

      June 2, 2022

      Student Corner

      Students’ Corner: A day in the life of a medical student in your country

      May 20, 2022

      Student Corner

      Student Teaser Fellowship winners 2022

      May 11, 2022

      Student Corner

      ‘Why Neurology?’ student essay competition: win a travel grant for a future EAN Congress!

      March 14, 2022

      E-Brain

      ebrain May update: new website and podcast series

      May 1, 2021

      E-Brain

      EBRA launches 3rd call for clusters

      May 1, 2020

      E-Brain

      News from ebrain

      February 28, 2020

      E-Brain

      ebrain to host the 2019 Neurology Formative Test Questions, from 15 April to 26 May

      April 1, 2019

      Grand Rounds

      eBrain: virtual case report from Belgium

      October 2, 2017

      Grand Rounds

      Free access to Ebrain for EAN members

      July 1, 2016

      Grand Rounds

      Ebrain granted Royal College of Physicians (UK) CPD/CME accreditation

      July 1, 2016

      Grand Rounds

      ebrain session of the month: neuromuscular junction

      February 1, 2016

      Resident and Research Fellows

      Workshop at EAN 2022 raises awareness of mentorship benefits

      July 5, 2022

      Resident and Research Fellows

      First ever UK Regional Teaching Course held in Liverpool, in person

      July 4, 2022

      Resident and Research Fellows

      RRFS Special Session – Unveiling research in Neurology: differences between basic, clinical and translational

      June 25, 2022

      Resident and Research Fellows

      23rd EAN Spring School – Report

      June 24, 2022

      Fellowship reports

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Fellowship reports

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      Fellowship reports

      Research Fellowship Report 2020 – Institut Necker Enfants Malades, Paris

      July 15, 2022

      Education corner

      Clinical Fellowship Reports 2022 – Oxford, Bern, London

      July 28, 2022

      Education corner

      Clinical Fellowship Reports 2021 – Bucharest & Padova

      July 15, 2022

      Education corner

      Research Fellowship Report 2021 – Inselspital Bern, Switzerland

      July 15, 2022

      Education corner

      Research Fellowship Report 2020 – Institut Necker Enfants Malades, Paris

      July 15, 2022

  • Other News
    • All EAN Staff Grant opportunities News from EAN member societies EBC EFNA News in general Patients societies reports Surveys Forum
      Other News

      The role of EAN in the European Medicine Agency

      August 2, 2022

      News from EAN member societies

      14 June: Special publication celebrates 10 years of the European Working Group of People with Dementia

      August 2, 2022

      News from EAN member societies

      14 June: Alzheimer Europe hosts European Parliament Lunch Debate examining EU and WHO policies on neurological conditions

      August 2, 2022

      News from EAN member societies

      22 June: Alzheimer Europe invites applications for its new Anti-Stigma Award

      August 2, 2022

      EAN Staff

      EAN Head Office Profiles: Patrycja & Martin

      July 28, 2022

      EAN Staff

      EAN Head Office Profiles: Anja S

      July 12, 2022

      EAN Staff

      EAN Head Office Profiles: Magda & Lindley

      June 7, 2022

      EAN Staff

      EAN Head Office Profiles: Julia & Maria

      April 4, 2022

      Grant opportunities

      1st EAN Science School, 26-29 March 2022: “Pathophysiology of disorders of the nervous system”

      June 18, 2021

      Grant opportunities

      European Commission: Innovation and novelty in medical devices and in vitro diagnostic devices; towards common concepts of innovation-related risk assessments

      November 1, 2019

      Grant opportunities

      GBS|CIDP Foundation International 2020 Research Grant Opportunity

      October 29, 2019

      Grant opportunities

      The Clinical Fellowship application deadline is approaching

      October 1, 2019

      News from EAN member societies

      14 June: Special publication celebrates 10 years of the European Working Group of People with Dementia

      August 2, 2022

      News from EAN member societies

      14 June: Alzheimer Europe hosts European Parliament Lunch Debate examining EU and WHO policies on neurological conditions

      August 2, 2022

      News from EAN member societies

      22 June: Alzheimer Europe invites applications for its new Anti-Stigma Award

      August 2, 2022

      News from EAN member societies

      Alzheimer Europe publishes new reports on ‘sex, gender and sexuality in the context of dementia’, and ‘dementia-inclusive initiatives and communities’

      April 5, 2022

      EBC

      Value of Treatment project releases results and calls to action

      March 29, 2022

      EBC

      Best practices for patient safety: An EU-wide view on the use of medicines off-label

      December 31, 2021

      EBC

      Creating synergies and showcasing innovation: Brain Innovation Days 2021

      November 30, 2021

      EBC

      Best practices for patient safety: Register now!

      October 28, 2021

      EFNA

      OneNeurology European Summit underlines urgent need to prioritise neurology and drive change

      December 31, 2021

      EFNA

      EFNA launch eLearning Platform for neurology advocates

      February 1, 2021

      EFNA

      ‘Me and My Brain’ – Art Competition winners announced!

      February 1, 2021

      EFNA

      Survey on the impact of COVID-19 on neurology service delivery

      November 1, 2020

      News in general

      EAN lecture at the International Neuro-Urology Society annual congress 2022

      May 25, 2022

      News in general

      EPA-EAN Joint Symposium: ‘Etiology and Treatment of the Long Covid-19 Syndrome’ and other highlights at the 30th European Congress of Psychiatry

      May 25, 2022

      News in general

      Organise an EAN-Day or EAN Regional Teaching Course in your Country!

      May 17, 2022

      News in general

      Value of Treatment project releases results and calls to action

      March 29, 2022

      Patients societies reports

      News from Alzheimer Europe

      March 2, 2020

      Patients societies reports

      News from the WHO

      January 9, 2020

      Patients societies reports

      News from EFIC and the European Pain Forum

      January 3, 2020

      Patients societies reports

      News from EFIC and the European Pain Forum

      January 2, 2020

      Surveys

      Survey: management of covert brain infarction

      October 29, 2021

      Surveys

      Driving with an intracranial tumor

      July 13, 2020

      Surveys

      SURVEY: Driving with an intracranial tumor

      June 25, 2020

      Surveys

      EAN SURVEY: Neurological Symptoms in COVID-19 Patients

      April 10, 2020

      Forum

      Call for Applications: e-Learning Platform Editor-in-Chief

      August 4, 2020

      Forum

      Neurological News from Denmark VI – the land of the 2nd EAN congress 2016: Pain Research in Denmark from a neurological perspective

      April 1, 2016

      Forum

      Neurological News from Denmark V – the land of the 2nd EAN congress 2016: Clinical Dementia Research in Denmark

      March 1, 2016

      Forum

      Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri – Comment to EMA recommendation

      March 1, 2016

Breaking newsCOVID-19

COVID-19 Breaking News: Randomised double-blinded placebo-controlled trials

January 11, 2022

Randomised double-blinded placebo-controlled trials (Orange)

Read on for our highlighted selection of Covid-related randomised double-blinded placebo-controlled trials from the scientific press for January 2022:

  • Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients
  • Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients
  • Subcutaneous REGEN-COV Antibody Combination to Prevent COVID-19
  • Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
  • Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
  • Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
  • Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
  • Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients
Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (COVID-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with COVID-19 who are at high risk for disease progression prevents hospitalization is uncertain. This randomized, double-blind, placebo-controlled trial involved nonhospitalized patients with COVID-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age ≥60 years, obesity, or certain coexisting medical conditions). Patients were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. The primary efficacy end point was a composite of COVID-19–related hospitalization or death from any cause by day 28. The primary safety end point was any adverse event. A secondary end point was a composite of a COVID-19–related medically attended visit or death from any cause by day 28.
A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%). COVID-19–related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.03 to 0.59; P=0.008). A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a COVID-19–related medically attended visit by day 28 (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group. The authors concluded that among nonhospitalized patients who were at high risk for COVID-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMoa2116846.


Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (COVID-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The authors of this article conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed COVID-19 and at least one risk factor for severe COVID-19 illness. Participants in the trial were randomly assigned to receive 800 mg of molnupiravir or placebo twice daily for 5 days. The primary efficacy end point was the incidence hospitalization or death at day 29; the incidence of adverse events was the primary safety end point. A planned interim analysis was performed when 50% of 1550 participants (target enrolment) had been followed through day 29.
A total of 1433 participants underwent randomization; 716 were assigned to receive molnupiravir and 717 to receive placebo. With the exception of an imbalance in sex, baseline characteristics were similar in the two groups. The superiority of molnupiravir was demonstrated at the interim analysis; the risk of hospitalization for any cause or death through day 29 was lower with molnupiravir (28 of 385 participants [7.3%]) than with placebo (53 of 377 [14.1%]) (difference, −6.8 percentage points; 95% confidence interval, −11.3 to −2.4; P=0.001). In the analysis of all participants who had undergone randomization, the percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, −3.0 percentage points; 95% confidence interval, −5.9 to −0.1). Results of subgroup analyses were largely consistent with these overall results; in some subgroups, such as patients with evidence of previous SARS-CoV-2 infection, those with low baseline viral load, and those with diabetes, the point estimate for the difference favored placebo. One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29. Adverse events were reported in 216 of 710 participants (30.4%) in the molnupiravir group and 231 of 701 (33.0%) in the placebo group.
Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with COVID-19.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N Engl J Med. 2021 Dec 16. doi: 10.1056/NEJMoa2116044.


Subcutaneous REGEN-COV Antibody Combination to Prevent COVID-19
REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (COVID-19). Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent COVID-19 in persons at high risk for infection because of household exposure to a person with SARS-CoV-2 infection is unknown. In this study the authors randomly assigned, in a 1:1 ratio, participants (≥12 years of age) who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200 mg of REGEN-COV or matching placebo administered by means of subcutaneous injection. At the time of randomization, participants were stratified according to the results of the local diagnostic assay for SARS-CoV-2 and according to age. The primary efficacy end point was the development of symptomatic SARS-CoV-2 infection through day 28 in participants who did not have SARS-CoV-2 infection (as measured by reverse-transcriptase–quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity).
Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P<0.001). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 participants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%). Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (>104 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted. The authors concluded that subcutaneous REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load.
O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent COVID-19. N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682.


Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (COVID-19) in phase 2b–3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America.
In this study the authors conducted a phase 3, randomized, observer-blinded, placebo-controlled trial in the United States and Mexico during the first half of 2021 to evaluate the efficacy and safety of NVX-CoV2373 in adults (≥18 years of age) who had not had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Participants were randomly assigned in a 2:1 ratio to receive two doses of NVX-CoV2373 or placebo 21 days apart. The primary objective was to determine vaccine efficacy against reverse-transcriptase–polymerase-chain-reaction–confirmed COVID-19 occurring at least 7 days after the second dose. Vaccine efficacy against moderate-to-severe disease and against different variants was also assessed. Of the 29,949 participants who underwent randomization between December 27, 2020, and February 18, 2021, a total of 29,582 (median age, 47 years; 12.6% ≥65 years of age) received at least one dose: 19,714 received vaccine and 9868 placebo. Over a period of 3 months, 77 cases of COVID-19 were noted — 14 among vaccine recipients and 63 among placebo recipients (vaccine efficacy, 90.4%; 95% confidence interval [CI], 82.9 to 94.6; P<0.001). Ten moderate and 4 severe cases occurred, all in placebo recipients, yielding vaccine efficacy against moderate-to-severe disease of 100% (95% CI, 87.0 to 100). Most sequenced viral genomes (48 of 61, 79%) were variants of concern or interest — largely B.1.1.7 (alpha) (31 of the 35 genomes for variants of concern, 89%). Vaccine efficacy against any variant of concern or interest was 92.6% (95% CI, 83.6 to 96.7). Reactogenicity was mostly mild to moderate and transient but was more frequent among NVX-CoV2373 recipients than among placebo recipients and was more frequent after the second dose than after the first dose. The authors concluded that NVX-CoV2373 was safe and effective for the prevention of COVID-19. Most breakthrough cases were caused by contemporary variant strains.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185.


Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, the authors report results on the final efficacy and interim safety analyses of the phase 3 trial.
This double-blind, randomised, international, placebo-controlled, endpoint-case driven, phase 3, clinical trial enrolled adults aged 18 years older at study centres in Argentina, Chile, Mexico, Pakistan, and Russia. Participants were eligible for the study if they had no unstable or severe underlying medical or psychiatric conditions; had no history of a laboratory-confirmed SARS-CoV-2 infection; were not pregnant or breastfeeding; and had no previous receipt of an adenovirus-vectored, coronavirus, or SARS-CoV-2 vaccine. 25 mL of whole blood was withdrawn from all eligible participants who were randomised in a 1:1 ratio to receive a single intramuscular dose of 0·5 mL placebo or a 0·5 mL dose of 5 × 1010 viral particle (vp)/mL Ad5-nCoV vaccine. All participants were contacted weekly by email, telephone, or text message to self-report any symptoms of COVID-19 illness, and laboratory testing for SARS-CoV-2 was done for all participants with any symptoms. The primary efficacy objective evaluated Ad5-nCoV in preventing symptomatic, PCR-confirmed COVID-19 infection occurring at least 28 days after vaccination in all participants who were at least 28 days postvaccination on Jan 15, 2021. The primary safety objective evaluated the incidence of any serious adverse events or medically attended adverse events postvaccination in all participants who received a study injection. Study enrolment began on Sept 22, 2020, in Pakistan, Nov 6, 2020, in Mexico, Dec 2, 2020, in Russia and Chile, and Dec 17, 2020, in Argentina; 150 endpoint cases were reached on Jan 15, 2021, triggering the final primary efficacy analysis. One dose of Ad5-nCoV showed a 57·5% (95% CI 39·7–70·0, p=0·0026) efficacy against symptomatic, PCR-confirmed, COVID-19 infection at 28 days or more postvaccination (21 250 participants; 45 days median duration of follow-up [IQR 36–58]). In the primary safety analysis undertaken at the time of the efficacy analysis (36 717 participants), there was no significant difference in the incidence of serious adverse events (14 [0·1%] of 18 363 Ad5-nCoV recipients and 10 [0·1%] of 18 354 placebo recipients, p=0·54) or medically attended adverse events (442 [2·4%] of 18 363 Ad5-nCoV recipients and 411 [2·2%] of 18 354 placebo recipients, p=0·30) between the Ad5-nCoV or placebo groups, or any serious adverse events considered related to the study product (none in both Ad5-nCoV and placebo recipients). In the extended safety cohort, 1004 (63·5%) of 1582 of Ad5-nCoV recipients and 729 (46·4%) of 1572 placebo recipients reported a solicited systemic adverse event (p<0·0001), of which headache was the most common (699 [44%] of Ad5-nCoV recipients and 481 [30·6%] of placebo recipients; p<0·0001). 971 (61·3%) of 1584 Ad5-nCoV recipients and 314 (20·0%) of 1573 placebo recipients reported an injection-site adverse event (p<0·0001), of which pain at the injection site was the most frequent; reported by 939 (59%) Ad5-nCoV recipients and 303 (19%) placebo recipients. The authors concluded that one dose of Ad5-nCoV is efficacious and safe in healthy adults aged 18 years and older.
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Halperin, Scott AMao, Helen et al. The Lancet, Volume 0, Issue 0. DOI: https://doi.org/10.1016/S0140-6736(21)02753-7.


Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Large-scale vaccination against COVID-19 is being implemented in many countries with CoronaVac, an inactivated vaccine. In this study the authors aimed to assess the immune persistence of a two-dose schedule of CoronaVac, and the immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18 years and older. In the first of two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, adults aged 18–59 years in Jiangsu, China, were initially allocated (1:1) into two vaccination schedule cohorts: a day 0 and day 14 vaccination cohort (cohort 1) and a day 0 and day 28 vaccination cohort (cohort 2); each cohort was randomly assigned (2:2:1) to either a 3 μg dose or 6 μg dose of CoronaVac or a placebo group. Following a protocol amendment on Dec 25, 2020, half of the participants in each cohort were allocated to receive an additional dose 28 days (window period 30 days) after the second dose, and the other half were allocated to receive a third dose 6 months (window period 60 days) after the second dose. In the other phase 2 trial, in Hebei, China, participants aged 60 years and older were assigned sequentially to receive three injections of either 1·5 μg, 3 μg, or 6 μg of vaccine or placebo, administered 28 days apart for the first two doses and 6 months (window period 90 days) apart for doses two and three. The main outcomes of the study were geometric mean titres (GMTs), geometric mean increases (GMIs), and seropositivity of neutralising antibody to SARS-CoV-2 (virus strain SARS-CoV-2/human/CHN/CN1/2020, GenBank accession number MT407649.1), as analysed in the per-protocol population (all participants who completed their assigned third dose). This report is focused on the 3 μg groups, since 3 μg is the licensed formulation.
540 (90%) of 600 participants aged 18–59 years were eligible to receive a third dose, of whom 269 (50%) received the primary third dose 2 months after the second dose (cohorts 1a-14d-2m and 2a-28d-2m) and 271 (50%) received a booster dose 8 months after the second dose (cohorts 1b-14d-8m and 2b-28d-8m). In the 3 μg group, neutralising antibody titres induced by the first two doses declined after 6 months to near or below the seropositive cutoff (GMT of 8) for cohort 1b-14d-8m (n=53; GMT 3·9 [95% CI 3·1–5·0]) and for cohort 2b-28d-8m (n=49; 6·8 [5·2–8·8]). When a booster dose was given 8 months after a second dose, GMTs assessed 14 days later increased to 137·9 (95% CI 99·9–190·4) for cohort 1b-14d-8m and 143·1 (110·8–184·7) 28 days later for cohort 2b-28d-8m. GMTs moderately increased following a primary third dose, from 21·8 (95% CI 17·3–27·6) on day 28 after the second dose to 45·8 (35·7–58·9) on day 28 after the third dose in cohort 1a-14d-2m (n=54), and from 38·1 (28·4–51·1) to 49·7 (39·9–61·9) in cohort 2a-28d-2m (n=53). GMTs had decayed to near the positive threshold by 6 months after the third dose: GMT 9·2 (95% CI 7·1–12·0) in cohort 1a-14d-2m and 10·0 (7·3–13·7) in cohort 2a-28d-2m. Similarly, in adults aged 60 years and older who received booster doses (303 [87%] of 350 participants were eligible to receive a third dose), neutralising antibody titres had declined to near or below the seropositive threshold by 6 months after the primary two-dose series. A third dose given 8 months after the second dose significantly increased neutralising antibody concentrations: GMTs increased from 42·9 (95% CI 31·0–59·4) on day 28 after the second dose to 158·5 (96·6–259·2) on day 28 following the third dose (n=29). All adverse reactions reported within 28 days after a third dose were of grade 1 or 2 severity in all vaccination cohorts. There were three serious adverse events (2%) reported by the 150 participants in cohort 1a-14d-2m, four (3%) by 150 participants from cohort 1b-14d-8m, one (1%) by 150 participants in each of cohorts 2a-28d-2m and 2b-28d-8m, and 24 (7%) by 349 participants from cohort 3-28d-8m. The authors concluded that a third dose of CoronaVac in adults administered 8 months after a second dose effectively recalled specific immune responses to SARS-CoV-2, which had declined substantially 6 months after two doses of CoronaVac, resulting in a remarkable increase in the concentration of antibodies and indicating that a two-dose schedule generates good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses.
Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021 Dec 7:S1473-3099(21)00681-2. doi: 10.1016/S1473-3099(21)00681-2.


Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, the authors studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).
Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8–12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine.
Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation. Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.
Stuart ASV, Shaw RH, Liu X, Com-COV2 Study Group. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021 Dec 6:S0140-6736(21)02718-5. doi: 10.1016/S0140-6736(21)02718-5.


Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, the authors investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer–BioNtech, hearafter referred to as BNT). COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19. Participants were aged older than 30 years, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection. 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C), participants were randomly assigned to an experimental vaccine or control. Group A received NVX-CoV2373 (Novavax; hereafter referred to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY)control (1:1:1:1). Group B received BNT, VLA2001 (Valneva; hereafter referred to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:1:1:1). Group C received mRNA1273 (Moderna; hereafter referred to as m1273), CVnCov (CureVac; hereafter referred to as CVn), a half dose of BNT, or MenACWY (1:1:1:1). Participants and all investigatory staff were blinded to treatment allocation. Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG measured by ELISA. The primary analysis for immunogenicity was on a modified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat population. Secondary outcomes included assessment of viral neutralisation and cellular responses. Between June 1 and June 30, 2021, 3498 people were screened. 2878 participants met eligibility criteria and received COVID-19 vaccine or control. The median ages of ChAd/ChAd-primed participants were 53 years (IQR 44–61) in the younger age group and 76 years (73–78) in the older age group. In the BNT/BNT-primed participants, the median ages were 51 years (41–59) in the younger age group and 78 years (75–82) in the older age group. In the ChAd/ChAD-primed group, 676 (46·7%) participants were female and 1380 (95·4%) were White, and in the BNT/BNT-primed group 770 (53·6%) participants were female and 1321 (91·9%) were White. Three vaccines showed overall increased reactogenicity: m1273 after ChAd/ChAd or BNT/BNT; and ChAd and Ad26 after BNT/BNT. For ChAd/ChAd-primed individuals, spike IgG geometric mean ratios (GMRs) between study vaccines and controls ranged from 1·8 (99% CI 1·5–2·3) in the half VLA group to 32·3 (24·8–42·0) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·1 (95% CI 0·7–1·6) for ChAd to 3·6 (2·4–5·5) for m1273. For BNT/BNT-primed individuals, spike IgG GMRs ranged from 1·3 (99% CI 1·0–1·5) in the half VLA group to 11·5 (9·4–14·1) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·0 (95% CI 0·7–1·6) for half VLA to 4·7 (3·1–7·1) for m1273. The results were similar between those aged 30–69 years and those aged 70 years and older. Fatigue and pain were the most common solicited local and systemic adverse events, experienced more in people aged 30–69 years than those aged 70 years or older. Serious adverse events were uncommon, similar in active vaccine and control groups. In total, there were 24 serious adverse events: five in the control group (two in control group A, three in control group B, and zero in control group C), two in Ad26, five in VLA, one in VLA-half, one in BNT, two in BNT-half, two in ChAd, one in CVn, two in NVX, two in NVX-half, and one in m1273. The authors concluded that all study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3.


COVID-19 Breaking News: Randomised double-blinded placebo-controlled trials was last modified: January 28th, 2022 by Simon Lee
Share this...
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
previous post
COVID-19 Breaking News: Interventional Studies with open label/non-randomised methodology
next post
First pairs matched in the EAN Mentorship Programme

You may also like

Evaluation of the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age

December 2, 2021

The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells

November 8, 2021

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

September 1, 2020

Breaking News – January 2022

January 14, 2022

Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death case

November 3, 2021

COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management

November 4, 2020

COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system

May 5, 2021

Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study

September 7, 2021

Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients

December 7, 2021

Worsened Parkinson’s Disease Progression: Impact of the COVID-19 Pandemic

September 7, 2021
EANcore COVID-19

Upcoming Events

Aug
26
Fri
all-day MDS-ES Online Course “Pump-based...
MDS-ES Online Course “Pump-based...
Aug 26 – Aug 28 all-day
MDS-ES Online Course “Pump-based Therapies in Advanced Parkinson´s Disease”
MDS-ES Online Course “Pump-based Therapies in Advanced Parkinson´s Disease” August 26 – 28, 2021 MDS- ES Pump-based Therapies in Advanced Parkinson´s Disease (movementdisorders.org) Visit the MDS website: www.movementdisorders.org This meeting…
Sep
25
Sun
all-day 6th Rijeka Forum on Neurodegener...
6th Rijeka Forum on Neurodegener...
Sep 25 – Sep 28 all-day
First announcement:  https://neuro-hr.org/Content/Documents/6th%20Rijeka%20forum%20on%20neurodegenerative%20diseases%20first%20announcem%20_9.5.2022..pdf Website: https://neurolab.uniri.hr/?page_id=24   This event has been endorsed by the EAN.Share this...FacebookTwitterLinkedin
Oct
11
Tue
all-day Brain Innovation Days 2022
Brain Innovation Days 2022
Oct 11 – Oct 12 all-day
The 2nd in-person Brain Innovation Days will take place over 1.5 days this year, on 11-12 October 2022. The 2022 event will centre around Connecting Brains: bringing together the current and future generations…
all-day European Brain Research Area – F...
European Brain Research Area – F...
Oct 11 all-day
The Final Conference of the EBC-coordinated European Brain Research Area (EBRA) project will take place on the morning of 11 October 2022 with a policy-focused event. Four years of EBRA…
Oct
14
Fri
all-day 26th Conference of the European ...
26th Conference of the European ...
Oct 14 – Oct 16 all-day
Website: https://neurosonology2022.esnch.org/ Programme overview: https://neurosonology2022.esnch.org/program/   This event has been endorsed by the EAN.Share this...FacebookTwitterLinkedin
View Calendar

Latest Tweets

  • Tweet Avatar
    EANeurology
    @EANeurology
    New #podcast episode out! This week we hear Thorsten Steiner and Barbara Tettenborn speak about about the #etiology… https://t.co/wHZMYkZ5Ov

    8 hours ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    Dr. Eveline Pajediene shared her thoughts in an interview back in June on how #long-covid affects sleep disorders,… https://t.co/hMvyV2WvRl

    2 days ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    Since May 2020, investigators globally have been collecting epidemiological data on neurological manifestations in… https://t.co/62dNql3uBg

    3 days ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    RT @WileyHealth: New #OpenAccess Guideline on the treatment of Parkinson's disease: I. Invasive therapies, from @EANeurology and… https://t.co/LMkMIu4pLS

    4 days ago
  • Tweet Avatar
    EANeurology
    @EANeurology
    RT @WileyNeuro: This month's #JournalSpotlight, European journal of #Neurology, impacts the field via published guidelines, special… https://t.co/K6gNDv6TcZ

    5 days ago

Keep in touch

Facebook Twitter Instagram
EAN Pages is a members service of the European Academy of Neurology https://www.ean.org

All content from January 2012 - June 2013 was published by EFNS; content from July 2013 - June 2014 by EFNS and ENS.

ISSN 2310-2934

Keep in touch

Facebook Twitter Instagram

Archives

Pages

  • Congress 2021
  • Privacy Policy
  • About us
  • Help
  • Contact

Back To Top